OTCMKTS:CHHE

China Health Industries Competitors

$0.20
-0.25 (-55.31 %)
(As of 05/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.20
$0.24
50-Day Range
$0.24
$0.49
52-Week Range
$0.19
$0.75
Volume300 shs
Average Volume2,481 shs
Market CapitalizationN/A
P/E Ratio3.37
Dividend YieldN/A
Beta1.67

Competitors

China Health Industries (OTCMKTS:CHHE) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying CHHE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to China Health Industries, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Acusphere (OTCMKTS:ACUS) and China Health Industries (OTCMKTS:CHHE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk & Volatility

Acusphere has a beta of -0.25, indicating that its share price is 125% less volatile than the S&P 500. Comparatively, China Health Industries has a beta of 1.67, indicating that its share price is 67% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Acusphere and China Health Industries, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
China Health Industries0000N/A

Profitability

This table compares Acusphere and China Health Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
China Health Industries34.11%8.60%7.05%

Valuation & Earnings

This table compares Acusphere and China Health Industries' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
China Health Industries$9.93 millionN/A$3.55 millionN/AN/A

China Health Industries has higher revenue and earnings than Acusphere.

Summary

China Health Industries beats Acusphere on 5 of the 5 factors compared between the two stocks.

China Health Industries (OTCMKTS:CHHE) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Risk & Volatility

China Health Industries has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Affymax has a beta of 2.77, suggesting that its share price is 177% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for China Health Industries and Affymax, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Health Industries0000N/A
Affymax0000N/A

Profitability

This table compares China Health Industries and Affymax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Health Industries34.11%8.60%7.05%
AffymaxN/AN/AN/A

Valuation and Earnings

This table compares China Health Industries and Affymax's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Health Industries$9.93 millionN/A$3.55 millionN/AN/A
AffymaxN/AN/AN/AN/AN/A

China Health Industries has higher revenue and earnings than Affymax.

Summary

China Health Industries beats Affymax on 4 of the 5 factors compared between the two stocks.

China Health Industries (OTCMKTS:CHHE) and ARYx Therapeutics (OTCMKTS:ARYX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Risk & Volatility

China Health Industries has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, ARYx Therapeutics has a beta of -0.53, suggesting that its share price is 153% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for China Health Industries and ARYx Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Health Industries0000N/A
ARYx Therapeutics0000N/A

Profitability

This table compares China Health Industries and ARYx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Health Industries34.11%8.60%7.05%
ARYx TherapeuticsN/AN/AN/A

Valuation and Earnings

This table compares China Health Industries and ARYx Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Health Industries$9.93 millionN/A$3.55 millionN/AN/A
ARYx TherapeuticsN/AN/AN/AN/AN/A

China Health Industries has higher revenue and earnings than ARYx Therapeutics.

Summary

China Health Industries beats ARYx Therapeutics on 5 of the 5 factors compared between the two stocks.

China Health Industries (OTCMKTS:CHHE) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Risk & Volatility

China Health Industries has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, suggesting that its share price is 971% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for China Health Industries and AtheroNova, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Health Industries0000N/A
AtheroNova0000N/A

Profitability

This table compares China Health Industries and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Health Industries34.11%8.60%7.05%
AtheroNovaN/AN/AN/A

Valuation and Earnings

This table compares China Health Industries and AtheroNova's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Health Industries$9.93 millionN/A$3.55 millionN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

China Health Industries has higher revenue and earnings than AtheroNova.

Summary

China Health Industries beats AtheroNova on 5 of the 5 factors compared between the two stocks.

China Health Industries (OTCMKTS:CHHE) and China Botanic Pharmaceutical (OTCMKTS:CBPI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Risk & Volatility

China Health Industries has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, China Botanic Pharmaceutical has a beta of 17.09, suggesting that its share price is 1,609% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for China Health Industries and China Botanic Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Health Industries0000N/A
China Botanic Pharmaceutical0000N/A

Valuation and Earnings

This table compares China Health Industries and China Botanic Pharmaceutical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Health Industries$9.93 millionN/A$3.55 millionN/AN/A
China Botanic PharmaceuticalN/AN/AN/AN/AN/A

China Health Industries has higher revenue and earnings than China Botanic Pharmaceutical.

Profitability

This table compares China Health Industries and China Botanic Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Health Industries34.11%8.60%7.05%
China Botanic PharmaceuticalN/AN/AN/A

Summary

China Health Industries beats China Botanic Pharmaceutical on 4 of the 5 factors compared between the two stocks.

China Dongsheng International (OTCMKTS:CDSG) and China Health Industries (OTCMKTS:CHHE) are both consumer staples companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current recommendations for China Dongsheng International and China Health Industries, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Dongsheng International0000N/A
China Health Industries0000N/A

Risk and Volatility

China Dongsheng International has a beta of 13.38, suggesting that its share price is 1,238% more volatile than the S&P 500. Comparatively, China Health Industries has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.

Valuation and Earnings

This table compares China Dongsheng International and China Health Industries' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Dongsheng InternationalN/AN/AN/AN/AN/A
China Health Industries$9.93 millionN/A$3.55 millionN/AN/A

China Health Industries has higher revenue and earnings than China Dongsheng International.

Profitability

This table compares China Dongsheng International and China Health Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Dongsheng InternationalN/AN/AN/A
China Health Industries34.11%8.60%7.05%

Summary

China Health Industries beats China Dongsheng International on 4 of the 5 factors compared between the two stocks.


China Health Industries Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05-44.2%$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.08-24.1%$0.00N/A0.00Gap Down
ARYX
ARYx Therapeutics
0.0$0.01-0.0%$0.00N/A0.00Gap Up
AHROQ
AtheroNova
0.0$0.02-0.0%$0.00N/A0.00Gap Down
CBPI
China Botanic Pharmaceutical
0.0$0.08-0.0%$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06-0.0%$0.00N/A0.00
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04-0.0%$0.00N/A0.00
FTCY
Global Future City
0.5$0.00-0.0%$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$35.90-5.0%$0.00N/A0.00Gap Up
HRBR
Harbor Diversified
0.0$2.05-5.9%$0.00$263.61 million0.00High Trading Volume
Gap Up
IPAH
Interpharm
0.2$0.00-0.0%$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00-0.0%$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02-8.7%$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05-0.0%$0.00N/A0.00Gap Up
NNBP
Nanobac Pharmaceuticals
0.0$0.00-0.0%$0.00N/A0.00
PARD
Poniard Pharmaceuticals
0.5$0.06-0.0%$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02-0.0%$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00-0.0%$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.06-16.7%$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03-0.0%$0.00N/A0.00
SYNI
Synvista Therapeutics
0.0$0.00-0.0%$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00-0.0%$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.02-0.0%$0.00N/A0.00
VOQP
VioQuest Pharmaceuticals
0.0$0.01-0.0%$0.00N/A0.00
This page was last updated on 5/6/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.